The Expanding Role of JAK Inhibitors in MF

The Expanding Role of JAK Inhibitors in MF
The Expanding Role of JAK Inhibitors in MF
CME, CPE
Ruben Mesa, MD
Release Date: June 16, 2021
Expiration Date: June 16, 2022

Join Dr. Mesa as he discusses new opportunities for JAK inhibitors in myelofibrosis (MF). Topics will include the ruxolitinib phase 3 COMFORT I and II trials, management of early-onset treatment-associated cytopenia, and outcomes associated with fedratinib in the JAKARTA and JAKARTA-2 trials

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit